Further, ARAC significantly increased the number of CD8+ tumor infiltrating lymphocytes and increased the CD8+/Tregs ratio, indicating that the treatment could reshape the tumor microenvironment to an immune-permissive state. Here, CD8A is linked to neoplasm.